IL-15 Superagonist N-803 Combined with Vaccine ETBX-071 in Recurrent Prostate Cancer Trial Launched
A clinical trial is underway to evaluate the efficacy of N-803 alone and in combination with ETBX-071 in patients with biochemically recurrent prostate cancer post-radiation.